Systolic and diastolic blood pressure showed a trend of increase at 2-, 3-, and 4-week intervals in the ibrutinib group rats compared to the control group rats, although the observed changes did not reach statistical significance ( Figure 2 D).
← all excerpts
Ibrutinib-induced pulmonary angiotensin-converting enzyme activation promotes atrial fibrillation in rats.
1
—
—